title: Polymorphism of Fc receptor (Fc gamma RII) is reflected in cytokine release and adverse effects of mIgG1 anti-CD3/TCR antibody during rejection treatment after renal transplantation.
authors.affiliation: Department of Medicine, University Hospital Nijmegen, The Netherlands.
authors.forename: W J
authors.initials: WJ
authors.lastname: Tax
authors.forename: L A
authors.initials: LA
authors.lastname: Frenken
authors.forename: C A
authors.initials: CA
authors.lastname: Glaudemans
authors.forename: W P
authors.initials: WP
authors.lastname: Tamboer
authors.forename: R A
authors.initials: RA
authors.lastname: Koene
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D016207:Cytokines / Q000096:biosynthesis*; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007262:Infusions, Intravenous; D007371:Interferon-gamma / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D016030:Kidney Transplantation / Q000276:immunology*; D011110:Polymorphism, Genetic; D017260:Receptor-CD3 Complex, Antigen, T-Cell / Q000276:immunology*; D017452:Receptors, IgG / Q000235:genetics*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D015850:Interleukin-6; D017260:Receptor-CD3 Complex, Antigen, T-Cell; D017452:Receptors, IgG; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma